Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.
Research and development of multi-target inhibitors has attracted increasing attention as anticancer therapeutics. B-RafV600E synergistically works with vascular endothelial growth factor receptor 2 (KDR) to promote the occurrence and progression of cancers, and the development of dual-target drugs simultaneously against these two kinds of kinase may offer a better treatment advantage. In this paper, docking and three-dimensional quantitative structure activity relationship (3D-QSAR) studies were performed on a series of dual B-Raf/KDR inhibitors with a novel hinge-binding group, [5,6]-fused bicyclic scaffold. Docking studies revealed optimal binding conformations of these compounds interacting with both B-Raf and KDR. Based on these conformations, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) 3D-QSAR models were constructed, and the best CoMFA (q²=0.542, r²=0.989 for B-Raf; q²=0.768, r²=0.991 for KDR) and CoMSIA models (q²=0.519, r²=0.992 for B-Raf; q²=0.849, r²=0.993 for KDR) were generated. Further external validations confirmed their predictability, yielding satisfactory correlation coefficients (r²pred=0.764 (CoMFA), r²pred=0.841 (CoMSIA) for B-Raf, r²pred=0.912 (CoMFA), r²pred=0.846 (CoMSIA) for KDR, respectively). Through graphical analysis and comparison on docking results and 3D-QSAR contour maps, key amino acids that affect the ligand-receptor interactions were identified and structural features influencing the activities were discussed. New potent derivatives were designed, and subjected to preliminary pharmacological evaluation. The study may offer useful references for the modification and development of novel dual B-Raf/KDR inhibitors.
School of Science, China Pharmaceutical University, Nanjing 211169, China. tuna888@126.com.
Hai-Chun
HC
Liu
School of Science, China Pharmaceutical University, Nanjing 211169, China. tangsanzhi@163.com.
San-Zhi
SZ
Tang
School of Science, China Pharmaceutical University, Nanjing 211169, China. luai071@163.com.
Shuai
S
Lu
School of Science, China Pharmaceutical University, Nanjing 211169, China. tran1021@126.com.
Ting
T
Ran
School of Science, China Pharmaceutical University, Nanjing 211169, China. wjnj12@163.com.
Jian
J
Wang
School of Science, China Pharmaceutical University, Nanjing 211169, China. yanminzhang_cpu@126.com.
Yan-Min
YM
Zhang
School of Science, China Pharmaceutical University, Nanjing 211169, China. fanqie0401@163.com.
An-Yang
AY
Xu
School of Science, China Pharmaceutical University, Nanjing 211169, China. lutao@cpu.edu.cn.|State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211169, China. lutao@cpu.edu.cn.
Tao
T
Lu
School of Science, China Pharmaceutical University, Nanjing 211169, China. ydchen@cpu.edu.cn.
Ya-Dong
YD
Chen
D062105:Molecular Docking Simulation; D048493:Proto-Oncogene Proteins B-raf / Q000032:analysis*; D021281:Quantitative Structure-Activity Relationship; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D042461:Vascular Endothelial Growth Factor A; D048493:Proto-Oncogene Proteins B-raf
3D-QSAR; B-Raf/KDR; [5,6]-fused bicyclic scaffolds; docking